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The main source of energy for brain and other organs is glucose. To obtain an energy for all 
tissue glucose has to come through glycolysis then as pyruvate is converting to acetyl-CoA 
due to pyruvate dehydrogenase complex (PDC) and finally join to citric acid cycle. What 
happens when one of these stages become disturb? Mutation in genes encoding subunits of 
PDC leads to pyruvate dehydrogenase deficiency. Abnormalities in PDC activity result in 
severe metabolic and broad brain malformations. For better understanding the development 
and mechanism of pyruvate dehydrogenase deficiency the murine model of this disease has 
been created. Studies on a murine model showed similar malformation in brain structures as 
in the patients suffered from pyruvate dehydrogenase deficiency such as reduced neuronal 
density, heterotopias of grey matter, reduced size of corpus callosum and pyramids.  There is 
still no effective cure for PDC-deficiency. Promising therapy seemed to be ketogenic diet, 
which substitutes glucose to ketone bodies as a source of energy. Studies have shown that 
ketogenic diet decrease lactic acidosis and inhibit brain malformations, but not the mortality 
in early childhood. The newest reports say that phenylbutyrate increases level of PDC in 
brain, because reduced level of inactive form of PDH. Experiments on human fibroblast and 
zebra fish PDC-deficiency model showed that phenylbutyrate is promising cure to PDC-
deficiency. This review summarizes the most important findings on the metabolic and 
morphological effects of PDC-deficiency and research for treatment therapy. 
Key words: pyruvate dehydrogenase deficiency, metabolic disorders, Leigh syndrome, 
phenylbutyrate, ketogenic diet 
 INTRODUCTION 
Glucose is the main source of energy for brain and other organs. To obtain energy for all 
tissue glucose has to come through glycolysis then as pyruvate is converted to acetyl-CoA due 
to pyruvate dehydrogenase complex (PDC) and finally join to tricarboxylic acid cycle. 
Abnormalities in PDC activity results in severe biochemical/cellular, metabolic and 
morphological/anatomical malformations. The most of study in this field was concerned of 
molecular/biochemical mechanism, but in this review, authors summarize primarily less 
numerous findings on the metabolic as well as morphological effects of PDC-deficiency and 
research for treatment therapy. 
 
PYRUVATE DEHYDROGENASE COMPLEX 
The pyruvate dehydrogenase complex (PDC) plays a key role in converting pyruvate to 
acetyl-Co. This irreversible oxidative decarboxylation of pyruvate to acetyl-CoA links the 
glycolytic pathway in the cytosol with the citric acid cycle in the mitochondria [19]. The 
pyruvate dehydrogenase is a huge complex built of three catalytic enzymes, which collaborate 
closely with each other. PDC is consist of E1 subunit (PDH) - having pyruvate dehydrogenase 
activity and catalyze pyruvate decarboxylation, E2 subunit - dihydrolipoamide 
acetyltransferase, which is responsible for acetylation of coenzyme and the E3 subunit -
dihydrolipoamide dehydrogenase - catalyze the regeneration of oxidized lipoamide form [36]. 
Furthermore, a PDC complex includes protein X, E1- specific kinase and phospo-E1 
phosphatase [37].  
The E1 component is a heterotetramer consisting of two subunits-  and . Its activity 
depends on its phosphorylated or dephosphorylated form [28]. The dephosphorylation 
converts E1 subunit to an active form and is regulated by specific phosphatase, which is one 
of components of PDC. Consequently, regulation of E1 subunit impacts the activity of whole 
complex. The organ where the accumulation of active form of PDC is the highest is the brain 
[[45]. In mammals PDH  component is known in two isoforms, which are encoded in two 
ways - PDHA1 gene in human’s somatic cells (Pdha1 in mouse) is located in a X 
chromosome and PDHA2 (Pdha2 in mouse) localized in chromosome 4 and expressed only in 
testis. The cognizance about E1 genetic record is very useful, due to many primary defects 
occurring in this region are the main reasons a PDC deficiency [8,29]. 
 
PYRUVATE DEHYDROGENASE DEFICIENCY AND ITS COROLLARY 
Pyruvate dehydrogenase deficiency is a congenital, metabolic disorder caused by 
incorrect version of gene encoding respective subunits of PDC. The faulty genes pertain to 
each of the complex subunits, but the E1  deficiency is the most frequent [35].Within 
mutation of E1 some missense/nonsense as well as deletions and insertions were noticed. 
Lissens and coworkers studied a group of 130 mutations. They discovered that insertions and 
deletions occurred on the exons 10 and 11 the most frequent and the missense/nonsense 
mutation appeared at all exons. There were also some sex differences, namely they found the 
missense/nonsense mutation in different exons in male and female. Furthermore, frequency of 
missense/nonsense mutation was lower in female [27]. Interestingly, the highest amount of 
mutation in E3 subdivision was observed in Ashkenazi Jews population [2]. There was also 
known case of missense mutation in gene encoding E2 component of PDC, which resulted in 
Paroxymal Exercise-Induced Dyskinesia [14].   
Glucose is the primary source of energy for every cell in the body. Because the brain is 
the most energy-demanding organ (brain glucose utilization accounts for approximately 80% 
of whole-body glucose disposal in humans), impaired glucose metabolism results mainly in 
morphological and hence functional changes of nervous structure. Commonly there were 
known two forms of pyruvate dehydrogenase disorder symptoms - metabolic (severe neonatal 
lactic acidosis, hyperlactacidemia, hyperpurvic acidemia) and neurological (congenital brain 
malformations like microcephaly, ventricular enlargement, periventricular leukomalacia, 
agenesis or absence of pons, corpus callosum, pyramid, likewise neurodevelopmental delay is 
observed). There were also some characteristic features in appearance noticed [6,9,21,57]. 
Barnerias et al. presented four neurological types comprising (1) malformations in corpus 
callosum and cortex that occur with early encephalopathy, (2) basal ganglia abnormalities and 
dysfunction of brainstem, (3) congenital motor disorders with paroxysmal dystonia or 
neuropathy and (4) chronic axonal neuropathy [3]. 
The disease, related with an abnormal activity of pyruvate dehydrogenase is the Leigh 
syndrome (subacute necrotizing encephalomyelopathy). Symptoms of this neurodegenerative 
congenital disorder were described by the first time in 1951 by Denis Leigh based on case of 
7-month old boy who died due to numerous cerebral abnormalities [26]. The subacute 
necrotizing encephalomyelopathy is the most frequent phenotype of mitochondrial diseases in 
children, affect in 1:40 000 live births [15,46]. Symptoms of this disorder occur in infancy or 
early childhood (3-12 months, 2nd year of life - the latest) [43,46]. Leigh syndrome was shown 
primarily in a neurological lesion in brain structures like ventriculomegaly, encephalopathy, 
changes in the grey matter, changes in basal ganglia; in the research of Lee and his teamwork 
the putamen was the most lesioned structure among the basal ganglia [13,25]. There were also 
pathological changes observed in medulla oblongata and midbrain, particularly in substantia 
nigra and red nucleus. Lesions in other brain areas like thalamus and cerebellum were also 
noticed. In the cerebellum atrophy as well in MRI studies T2 hyperintensity was observed in 
hemispheres as well as in vermis  
Therefore, as a conclusion, this is important to mention that among morphological effects 
of an abnormal activity of pyruvate dehydrogenase a particularly large number applies of 
brain structures involved in motor function (basal ganglia, cerebellum, red nucleus, pyramids) 
and cognitive function (cerebral cortex, dentate gyrus, corpus callosum) are involved. 
Whether is this associated with a higher energy demand for cells in these structures remains 
an open question and requires further research. 
 
MURINE MODEL OF PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY 
The pyruvate dehydrogenase complex deficiency and its consequences are neither 
completely understood nor no fully effective medicine is discovered. For this reason, 
scientists from Buffalo University developed murine model of pyruvate dehydrogenase 
complex deficiency with deletion of Pdha1 gene. To make it happen they used Cre-loxP 
recombination to delete Pdha1 gene encoding alfa subunit of E1 component [17,22,31]. 
Amount of alive progeny were reduced, furthermore only female pups survived. The null 
mutation was lethal for male progeny [41,42] . Obtained animal model of PDC deficiency 
showed similar features as cases of human PDC deficiency described in other publication, 
therefore it became a promising tool in PDC deficiency studies. 
 
MURINE MODEL OF PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY 
IN RESEARCHES 
Pyruvate dehydrogenase complex is an important factor in a glucose homeostasis and 
glucose is the main energy substrate for a brain [10]. Therefore, as was mentioned above, the 
malformations caused by deficiency in PDC occur mostly in a brain. The experiments on a 
murine model of PDC demonstrated a numerous deformities and abnormalities in brain 
structures in comparison to control animals. Researches of Buffalo University used the MR 
imaging, spectroscopy studies and ADC mapping to evaluate the lesions. The analysis of 
brain structures in experimental animals showed plenty of morphological and histological 
changes. Thickness of neocortex was decreased as well as pyriform cortex; density of 
pyramidal neurons was dramatically reduced. Heterotopias in forebrain particularly in caudate 
nucleus/putamen, changes in architecture of thalamus- reduced neuronal density in 
paraventricular, anterodorsal, lateral and medial nuclei, reduced thickness of corpus callosum, 
reduced size of anterior commissure and lateral olfactory tract and enlarged lateral ventricle 
were observed. Some structures of forebrain were underdeveloped as well. They also 
observed disorganization of neuronal axons in pyramidal decussation, anterior commissure, 
trigeminal lemniscus, dorsal tegmental decussation, rubrospinal tract and lateral olfactory 
tract. Some malformations in cerebellum also were observed - the most conspicuous feature 
was the general size of this structure which were smaller than in control group also reduced 
size of cerebellar hemisphere cortex, particularly density of Purkinje and granular neurons as 
well as cerebellar peduncles. In molecular layer they observed reduced amount of fibers so its 
general size was decreased. ADC analysis confirm significant cell loss and changes in brain 
structures. As expected, observed malformations correspond with altered brain tissue 
observed in the human suffered from PDC deficiency [41,42]. The important aspects of PDC 
deficiency were also biochemical parameters, particularly activity of PDC. Results of this 
analysis showed that transgenic female mice had wild-type as well as PDC-deficient cells in 
the brain. The activity of active form and total PDC was reduced by 25% compared with 
control female mice. Homogenates of brains from PDC- deficient demonstrated reduced level 
of  and ß subunits of PDH in PDC-deficient animals [42].  
Transgenic animals were examined on the different stages during development. Previous 
studies reported that developing brain demands a lot of energy sources right after birth and a 
PDC level significantly increases in this period [20,51,54]. Developmental studies 
demonstrated that the disturbances in PDC activity impairs differentiation and proliferation of 
neuron cells in both prenatal and postnatal periods. Analysis of brain structures confirmed 
previous observation like reduction of white matter structures, thickness of neocortex and 
heterotopias in grey matter. [41,42]. Furthermore, they observed gliosis and significant 
decrease of neuron number. In a given work were behavioral tests performed as well. 
Obtained results demonstrated that mice with PDC-deficiency suffered from neurological 
disorders [39]. 
Brain was not the only structure investigated in mice with PDC-deficiency. Because of 
important role of PDC in glucose homeostasis and lipid synthesis also liver seemed to be 
important subject to researches. Choi et al. [7] developed PDC-deficiency mice model with 
deletion of PDC specific for liver. As a result, they observed reduced body mass in transgenic 
mice. These studies were based on observation of the carbon movement via PDC and 
investigated its role in biosynthesis of lipids and generation an energy. The sensitivity of 
insulin was also examined: the results showed that in liver and in other tissues the sensitivity 
of insulin was enhanced. It was suspected that improved sensitivity arises out of the need to 
keep the normal rates of oxidative phosphorylation, which demand increased usage of free 
fatty acid [7]. To take a closer look at insulin management in PDC- deficiency one more 
specific murine model was created. Result showed that acetylo-CoA, which come from 
pyruvate oxidation due a PDC was very important factor participating in processes involved 
in insulin secretion from ß -cells [48].  
 
COULD WE FIND A CURE? 
The oldest applied therapy in PDC deficiency was the ketogenic diet. In the early 20th 
century the ketogenic diet was used as a treatment for epilepsy and uncontrolled seizures but 
afterward it was superseded by antiepileptic drugs. These days the diet is still in use, but 
mostly in drug-resistant epilepsy [1,33,55]. The aim of ketogenic diet is to substitute the fuel 
source from carbohydrates to ketone bodies and get effect similar to long-term fasting. In 
normal condition the energy in human organism is acquired from glucose. During ketogenic 
diet energy is derived from fatty acid oxidation [4,18]. Several studies reported that ketone 
bodies have neuroprotective effect as they influence to mitochondrial activity improved ATP 
production and decrease production of free radicals. The influence of ketogenic diet to 
nervous system is also significant for GABA signaling in neurons as well as supervise the 
work of neuronal synapses [30,50,56]. Ketogenic diet could be also applied in diverse 
neurological disorders such as Alzheimer disease, Parkinson disease, amyotrophic lateral 
sclerosis, strokes and other mitochondrial disorders [50]. The abnormality in PDC deficiency 
arises from incorrect converting pyruvate, which is a product of glycolysis to acetylo-CoA, 
which is a substrate in tricarboxylic acid cycle [34]. In case of disorder connected with a 
carbohydrate metabolism ketogenic diet seems to be a perfect solution to reinstate an energy 
balance. But what the results have shown. Sofou and coworkers examined a group of 19 
PDC-deficient children of different age. Results of ketogenic diet treatment showed positive 
effect on lactic acidosis, because the level of lactate significantly decreased. In pediatric 
patients with epileptic seizures reduced frequency or even completely suspension were 
observed. Improvement was noticed also in neurocognitive functioning as well as motor 
function. However, the ketogenic diet therapy did not significantly affected life expectancy 
(median in this study was 6 years) [47].The beneficial effects like stabilization and inhibition 
of expending the brain abnormalities were also observed in other studies [38,53]. The effects 
of ketogenic diet had been also investigated in mice model of PDC- deficiency with the 
difference that, the special diet was applied to pregnant animals and then during lactation. 
Therefore, they examined effects of treatment on the progeny. The brain structures in studied 
progeny (with feeding fat-rich diet) were much better improved than in control group, 
especially in neocortex, organization of neurons fibers and cerebellar structures. Furthermore, 
no structural abnormalities in forebrain and brainstem structures were observed. This study 
concluded that ketogenic diet during prenatal and early postnatal period was gainful for PDC-
deficient mice progeny [40]. 
The administration of thiamine pyrophosphate (TPP) as an additional treatment can 
potentially be effective, given its role as an obligate cofactor for the E1 component of the 
PDC complex. Many cases of PDC deficiency involved a pathological mutation affecting the 
thiamine pyrophosphate binding site of E1, supplementation with high doses of thiamine 
seems justified. The TPP treatment showed improved the clinical outcome like suspension of 
ataxia episodes and/or reduced lactate acidosis. These results were confirmed by in vitro 
studies showing a thiamine-responsive functional defect in the activities of PDHC and E1 in 
the lymphoblastoid cells cultured as well as in muscles and fresh mononuclear cells. Results 
showed that measurement of TPP is essential in low as well as high activity of PDHC to 
determine the thiamine responsiveness. [3,16,24,44] 
Dichloroacetate (DCA) stimulates the activity of the PDC by inhibiting the 
phosphorylation (and inactivation) of the E1α subunit of PDC complex. In some patients with 
E1α deficiency, DCA may also stabilize the enzyme and decrease its rate of turnover. 
Several studies had reported that the chronic, oral administration of dichloroacetate has been 
beneficial for patients with PDC deficiency or some patients with respiratory chain defects. 
DCA treatment was effective in reducing blood, CSF, or brain lactate concentrations and in 
improving quality of live. However, cases of peripheral neuropathy and hepatocellular 
toxicity has been noted [5,23,32,49] 
Phenylbutyrate seems to be a promising therapy in PDC- deficiency. This compound 
is well known and applied in other therapies such as urea cycle disorder, so the activity and 
effects on healthy tissue is well-known [52]. Experiments tested in human fibroblasts and 
zebra model of PDC-deficiency showed that phenylbutyrate increased activity of PDC in 
brain and other organs. This is because the phenylbutyrate affect the PDC Kinase and inhibits 
it - in consequences the phosphorylated (inactive) form of PDH is reduced, whereas the 
dephosphorylated form (active) was predominant. Furthermore, the systemic lactic acidosis 
was reduced [12]. Interestingly, phenylbutyrate in combination with dichloroacetate is much 
more effective in increasing the activity of PDC in mice. However, the toxicity of these drugs 
combination is unexplored and demand further tests [11]. The impact of phenylbutyrate on 
PDC complex activity and its result in brain and other tissue is still examined.  
 
CONCLUSIONS 
Pyruvate dehydrogenase deficiency is a serve metabolic and neurological disorder. 
Despite many promising therapies applied to patients no one is completely effective. Ideally, 
ketogenic diet should be applied to pregnant mothers and to infants immediately after birth, 
unfortunately the knowledge about disorder comes too late. Phenylbutyrate, which reduced 
level of inactive form of PDH is safe for healthy tissue and seems to be hopeful weapon 
against PDC- deficiency. This therapy however, demands further examination.  
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